




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b>  <b>C07D 471/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/17199</b>  <b>(43) International Publication Date:</b> 30 March 2000 (30.03.00)
<b>(21) International Application Number:</b> PCT/EP99/07003  <b>(22) International Filing Date:</b> 15 September 1999 (15.09.99)  <b>(30) Priority Data:</b> 9820405.0 18 September 1998 (18.09.98) GB  <b>(71) Applicant (for all designated States except US):</b> SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HAYES, Jerome, Francis [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). WALSGROVE, Timothy, Charles [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). WELLS, Andrew, Stephen [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB).  <b>(74) Agent:</b> BLAKEY, Alison, Jane; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> PROCESS FOR THE PRODUCTION OF A NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE (METHANESULFONATE SESQUIHYDRATE)  <div style="text-align: center;">  </div> <p style="text-align: right;">(I)</p>		
<b>(57) Abstract</b>  <p>The present invention relates to an improved process for the production of the methanesulfonate sesquihydrate which comprises direct salt and hydrate formation. According to the invention there is provided a process for the production of 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate sesquihydrate which comprises reacting 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid of formula (I) having antibacterial activity and methanesulfonic acid in a solvent comprising at least one water miscible cosolvent and water, and isolating the resulting solid product.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

# PROCESS FOR THE PRODUCTION OF A NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE (METHANESULFONATE SESQUIHYDRATE)

The present invention relates to a process for the production of a naphthyridine carboxylic acid derivative having antibacterial activity.

5 EP 688772 discloses novel naphthyridine carboxylic acid derivatives, including anhydrous (R,S)-7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid of formula I, having antibacterial activity.



I

10 WO 98/42705 (published after the priority date of the present application) discloses (R,S)-7-(3-aminomethyl-4-*syn*-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof including the sesquihydrate (the "methanesulfonate sesquihydrate").

15 WO 98/42705 discloses a process for the production of the methanesulfonate sesquihydrate comprising reaction of the corresponding free base with methanesulfonic acid in dichloromethane / ethanol followed by recrystallisation of the resulting crude salt anhydrate from either water : acetone (10:7 v/v), or water : ethanol (1:2 v/v). The overall yield for this two step process is 70-80%. An alternative process for the production of the

20 methanesulfonate sesquihydrate described in WO 98/42705 comprises exposing a solvate of the methanesulfonate (ethanol 0.11%) to high relative humidity (nitrogen >93% humidity).

The present invention relates to an improved process for the production of the methanesulfonate sesquihydrate which comprises direct salt and hydrate formation.

25 According to the invention there is provided a process for the production of 7-(3-aminomethyl-4-*syn*-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate sesquihydrate which comprises reacting 7-(3-aminomethyl-4-*syn*-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and

30 methanesulfonic acid in a solvent comprising at least one water miscible cosolvent and water, and isolating the resulting solid product.

The 7-(3-aminomethyl-4-*syn*-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (hereinafter referred to as "the free base") used in the process of the invention may be prepared as described in EP 688772.

5 Water miscible cosolvents which may be used in the process of the invention include C<sub>1-8</sub> alcohols, acetonitrile and dimethylformamide. The water miscible cosolvent is preferably a C<sub>1-4</sub> alcohol or a mixture thereof, e.g. methanol, ethanol and propanol; the preferred C<sub>1-4</sub> alcohol is isopropanol.

10 In addition to at least one water miscible cosolvent and water the solvent may contain other components, such as C<sub>1-4</sub> haloalkanes. However, the solvent preferably comprises essentially of a water miscible cosolvent and water.

Suitable ratios of water miscible cosolvent : water for use in the process of the invention include ratios in the range 10:1 to 1:2 v/v, preferred ratios are in the range 10:1 to 1:1 v/v, more preferably a ratio of water miscible cosolvent : water of 2:1 v/v is used.

15 Any suitable ratio of free base to solvent may be used, for example, a ratio of up to 1:100 w/v, particularly a ratio of about 1:9 w/v.

The process of the invention may suitably use from 0.7 to >3 mole equivalents of methanesulfonic acid, preferably 0.7 to 1.5 equivalents, more preferably 0.9 to 1.5 equivalents, especially about 1.0 equivalent of methanesulfonic acid (based on the free base).

20 The mixture of the free base and methanesulfonic acid may be warmed in the solvent to aid dissolution. On cooling the methanesulfonate sesquihydrate will crystallise out of solution. To aid crystallisation the solution may be seeded with a small quantity of solid methanesulfonate sesquihydrate. In order to obtain polymorphically pure  
25 methanesulfonate sesquihydrate it is preferable that seeding of the solution is completed before crystallisation begins. Seeding of the crystallisation solution is preferably performed at a temperature  $\geq 25^{\circ}\text{C}$ , for example at a temperature of about  $30^{\circ}\text{C}$ .

The process of the invention may be used to produce racemic methanesulfonate sesquihydrate or may be used for the production of enantiomerically enriched or  
30 enantiomerically pure methanesulfonate sesquihydrate, using racemic or enantiomerically enriched or enantiomerically pure free base. Enantiomerically enriched or enantiomerically pure free base may be prepared by resolution of the racemic free base, e.g. by chiral HPLC.

35 The process according to the invention has the advantage that direct salt formation eliminates one step in the synthesis and gives a high yield of high purity methanesulfonate sesquihydrate. In turn these advantages result in improved throughput and savings in labour and materials costs during manufacture.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication

were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The invention is illustrated by the following example. However, it should be understood that the example is intended to illustrate but not in any manner limit the scope of the invention.

Example 1 : Preparation of the methanesulfonate sesquihydrate

To a suspension of (R,S)-7-(3-aminomethyl-4-*syn*-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (20.00 g, 51.4 mmol) in isopropanol (120 ml) and water (60 ml) was added methanesulfonic acid (3.300 ml, 50.9 mmol) at 38-40°C. The resultant dark brown solution was stirred for 15 min after which time charcoal (6.00 g of Darco G-60) was added. The suspension was stirred at 38-40°C for 4h then filtered. The filtrate was allowed to cool to 30°C and seed crystals of (R,S)-7-(3-aminomethyl-4-*syn*-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate sesquihydrate (15 mg) added. A precipitate began to form within 15 min. The suspension was allowed to cool to 20-23°C over 90 min and was stirred for 36h. The slurry was cooled to 0-5°C for 60 min then filtered and washed with isopropanol (50 ml and 44 ml). The product was sucked dry for 30 min and then further dried at 50-55°C under vacuum. The dried product was exposed to the atmosphere for 18h to give the methanesulfonate sesquihydrate 21.29 g (85%), purity >99.5% by HPLC.

The X-ray diffraction pattern of the methanesulfonate sesquihydrate was measured as follows:

	Diffraction type:	PW1710 BASED
25	Tube anode:	Cu
	Generator tension [kV]:	40
	Generator current [mA]:	30
	Wavelength Alpha1 [Å]:	1.54060
	Wavelength Alpha2 [Å]:	1.54439
30	Intensity ratio (alpha1/alpha2):	0.500
	Divergence slit:	AUTOMATIC
	Irradiated length [mm]:	12
	Receiving slit:	0.1
	Spinner:	ON
35	Monochromator used:	YES
	Start angle [°2θ]:	3.500
	End angle [°2θ]:	35.000
	Step size [°2θ]:	0.020

	Maximum intensity:	2970.250
	Time per step [s]:	2.300
	Type of scan:	STEP
	Minimum peak tip width:	0.10
5	Maximum peak tip width:	1.00
	Peak base width:	2.00
	Minimum significance:	0.50

The X-ray diffraction pattern of the methanesulfonate sesquihydrate is shown in Figure 1. The compound shows characteristic peaks at  $2\theta = 8.2, 12.2$  and  $14.6^\circ$ .

10


CLAIMS

1. A process for the production of 7-(3-aminomethyl-4-*syn*-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate sesquihydrate which comprises  
5 reacting 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and methanesulfonic acid in a solvent comprising at least one water miscible cosolvent and water, and isolating the resulting solid product.
- 10 2. A process according to claim 1 wherein the water miscible cosolvent is a C<sub>1-4</sub> alcohol.
3. A process according to claim 2 wherein the water miscible cosolvent is  
15 isopropanol.
4. A process according to any one of the preceding claims wherein the ratio of water miscible cosolvent : water is in the range 10:1 to 1:2 v/v.
- 20 5. A process according to claim 4 wherein the ratio of water miscible cosolvent : water is 2:1 v/v.
6. A process according to any one of the preceding claims wherein the ratio of 7-(3-aminomethyl-4-*syn*-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : solvent is up to 1:100 w/v.  
25
7. A process according to any one of the preceding claims which uses from 0.7 to mole 1.5 equivalents of methanesulfonic acid.
- 30 8. A process according to any one of the preceding claims wherein the recrystallisation solution is seeded with 7-(3-aminomethyl-4-*syn*-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate sesquihydrate to aid crystallisation.
- 35 9. A process according to claim 8 wherein the solution is seeded whilst at a temperature of  $\geq 25^{\circ}\text{C}$ .
10. A process according to claim 9 wherein the solution is seeded whilst at a

temperature of about 30°C.



1/1

FIGURE 1

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 99/07003

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07D471/04

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 688 772 A (LG CHEMICAL LIMITED) 27 December 1995 (1995-12-27) cited in the application * see page 9, line 29-36 * the whole document ---	1-10
Y	WO 96 39406 A (HANDANYAN LYNNE A ; JOHNSON PHILLIP J (US); MORRIS THOMAS A (US); N) 12 December 1996 (1996-12-12) * see page 1, formula 1, and page 4, preparation A * the whole document ---	1-10
Y	WO 91 02526 A (PFIZER) 7 March 1991 (1991-03-07) the whole document ---	1-10
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

31 January 2000

Date of mailing of the international search report

01/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Stellmach, J

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 99/07003

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 805 156 A (KYORIN SEIYAKU KK) 5 November 1997 (1997-11-05) the whole document ----	1-10
Y	EP 0 058 614 A (BELLON LABOR SA ROGER ;DAINIPPON PHARMACEUTICAL CO (JP)) 25 August 1982 (1982-08-25) the whole document ----	1-10
Y	WO 97 36874 A (SMITHKLINE BEECHAM CORP ;DUDDU SARMA (US); PALEPU NAGESWARA R (US)) 9 October 1997 (1997-10-09) the whole document ----	1-10
Y	WO 97 07098 A (PFIZER ;ANDINO MARTA M (US); SINAY TERRY G (US); FIESE EUGENE F (U) 27 February 1997 (1997-02-27) the whole document ----	1-10
Y	PATENT ABSTRACTS OF JAPAN vol. 015, no. 202 (C-0834), 23 May 1991 (1991-05-23) & JP 03 056479 A (TAKESHI YOKOTA), 12 March 1991 (1991-03-12) abstract ----	1-10
P,X	WO 98 42705 A (CHOI HOON ;KIM AE RI (KR); LEE JIN HWA (KR); LEE TAE HEE (KR); NAM) 1 October 1998 (1998-10-01) cited in the application the whole document ----	1-10
E	WO 99 61420 A (UPJOHN CO ;RUNGE THOMAS A (US)) 2 December 1999 (1999-12-02) the whole document -----	1-10

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/07003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0688772 A	27-12-1995	KR 131999 B	17-04-1998
		CA 2151890 A,C	17-12-1995
		CN 1114959 A	17-01-1996
		DE 69509442 D	10-06-1999
		DE 69509442 T	02-09-1999
		JP 2742248 B	22-04-1998
		JP 8041050 A	13-02-1996
		US 5869670 A	09-02-1999
		US 5962468 A	05-10-1999
		US 5633262 A	27-05-1997
		US 5698570 A	16-12-1997
		US 5840916 A	24-11-1998
		US 5776944 A	07-07-1998
WO 9639406 A	12-12-1996	CA 2223404 A	12-12-1996
		HU 9601540 A	28-02-1997
		AU 703634 B	25-03-1999
		AU 5474996 A	19-12-1996
		BG 100639 A	28-02-1997
		BR 9602630 A	08-09-1996
		CN 1148596 A	30-04-1997
		CZ 9601625 A	16-09-1998
		DE 69503066 D	23-07-1998
		DE 69503066 T	15-10-1998
		EP 0789697 A	20-08-1997
		ES 2117426 T	01-08-1998
		FI 974441 A	05-12-1997
		HR 960267 A	31-08-1997
		IL 118488 A	26-01-1999
		JP 10506650 T	30-06-1998
		LV 11619 A	20-12-1996
		LV 11619 B	20-04-1997
		NO 962321 A	09-12-1996
		NZ 286735 A	26-01-1998
		PL 314604 A	09-12-1996
		SG 54339 A	16-11-1998
		SI 9600185 A	30-04-1997
		SK 71996 A	05-03-1997
		US 5763454 A	09-06-1998
WO 9102526 A	07-03-1991	AT 124040 T	15-07-1995
		AU 623801 B	21-05-1992
		AU 6104290 A	21-02-1991
		CA 2023217 A,C	17-02-1991
		CA 2127561 A	17-02-1991
		CN 1049501 A,B	27-02-1991
		CZ 9004027 A	17-04-1996
		CY 1969 A	05-09-1997
		DD 298399 A	20-02-1992
		DE 69020262 D	27-07-1995
		DE 69020262 T	26-10-1995
		DK 413455 T	14-08-1995
		EG 19251 A	29-09-1994
		EP 0413455 A	20-02-1991
		ES 2074131 T	01-09-1995
		FI 964520 A	11-11-1996
		GR 3017072 T	30-11-1995
		HK 1000207 A	06-02-1998

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/07003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9102526 A		IE 66202 B	13-12-1995
		IL 95331 A	31-07-1995
		JP 7149758 A	13-06-1995
		JP 8019099 B	28-02-1996
		JP 1975517 C	27-09-1995
		JP 3086875 A	11-04-1991
		JP 7002734 B	18-01-1995
		KR 9304844 B	09-06-1993
		LU 90310 A	25-01-1999
		LU 90311 A	25-01-1999
		NO 300214 B	28-04-1997
		NZ 234920 A	25-06-1992
		PL 166381 B	31-05-1995
		PT 94998 A, B	18-04-1991
		RU 2049777 C	10-12-1995
		US 5266569 A	30-11-1993
		US 5164402 A	17-11-1992
		US 5229396 A	20-07-1993
EP 0805156 A	05-11-1997	JP 8176143 A	09-07-1996
		AU 694946 B	06-08-1998
		AU 3994695 A	10-07-1996
		US 5880283 A	09-03-1999
		CA 2208704 A	27-06-1996
		CN 1171108 A	21-01-1998
		HU 77945 A	28-12-1998
		WO 9619472 A	27-06-1996
EP 0058614 A	25-08-1982	JP 1618494 C	12-09-1991
		JP 2043753 B	01-10-1990
		JP 57134482 A	19-08-1982
		AU 547082 B	03-10-1985
		AU 8017382 A	19-08-1982
		CA 1216292 A	06-01-1987
		CS 8200998 A	16-07-1987
		DD 202573 A	21-09-1983
		DK 63482 A, B,	14-08-1982
		ES 509538 A	01-08-1983
		FI 820466 A, B,	14-08-1982
		KR 8700322 B	27-02-1987
		MX 158194 A	16-01-1989
		NO 820430 A, B,	16-08-1982
		PH 18177 A	12-04-1985
		PL 235049 A	27-09-1982
		US 4442101 A	10-04-1984
		YU 26582 A	30-04-1986
		ZA 8200740 A	29-12-1982
WO 9736874 A	09-10-1997	AU 2547097 A	22-10-1997
		BR 9708336 A	03-08-1999
		CN 1214682 A	21-04-1999
		CZ 9803101 A	17-03-1999
		EP 0889880 A	13-01-1999
		NO 984503 A	28-09-1998
		NZ 332008 A	28-05-1999
		PL 329046 A	01-03-1999
		SK 132298 A	10-03-1999

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/07003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9707098 A	27-02-1997	AU 710984 B	07-10-1999
		AU 5908496 A	12-03-1997
		BG 102289 A	30-09-1998
		BR 9610766 A	13-07-1999
		CA 2228752 A	27-02-1997
		CN 1198739 A	11-11-1998
		CZ 9800390 A	17-02-1999
		EP 0843661 A	27-05-1998
		HR 960372 A	30-04-1998
		HU 9802862 A	28-04-1999
		JP 10510552 T	13-10-1998
		NO 980574 A	10-02-1998
		NZ 309134 A	29-09-1999
		PL 325050 A	06-07-1998
JP 03056479 A	12-03-1991	NONE	
WO 9842705 A	01-10-1998	AU 6636698 A	20-10-1998
		NO 994595 A	21-09-1999
WO 9961420 A	02-12-1999	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**